Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Recent publication
The Divisions of Pharmacology, Molecular Oncology and Haematology and the Division of Internal Medicine 2 at the University Hospital Krems are working together on strategies to fight cancer. Their basic research contributes significantly to both a deeper understanding of cellular mechanisms and the development of new treatment strategies. How does the immune system react to malignant cells and how do cancer cells evade immune control? In a recent study published in the Blood Cancer Journal, the research group highlights the essential role of the transcription factors MYC and JUNB in the pathogenesis of multiple myeloma. Specifically, they showed that MYC and JUNB control two distinct transcriptional programmes. Using in vitro models, the researchers showed that these transcriptional cascades are independent of each other. While JUNB is not affected when MYC is downregulated, MYC is not affected by JUNB knockout. This breakthrough opens up new promising therapeutic approaches for patients with multiple myeloma by combining two targeted therapies effectively and synergistically.
Lind, J, Aksoy, O, Prchal-Murphy, M, Fan, F, Fulciniti, M, Stoiber, D, Bakiri, L, Wagner, EF, Zwickl-Traxler, E, Sattler, M, Kollmann, K, Vallet, S & Podar, K 2024, 'Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity', Blood Cancer Journal, vol. 14, no. 1, 138. https://doi.org/10.1038/s41408-024-01117-4
Dr. Osman Aksoy
Scientific Staff (PostDoc)
Department of Molecular Oncology and Hematology
Univ.-Prof. PD MMag. Dr. Dagmar Stoiber-Sakaguchi
Head of
Department of Pharmacology
Mag. Elisabeth Zwickl-Traxler
Scientific Staff (PreDoc)
Division of Internal Medicine 2 (University Hospital Krems)
OÄ PD Dr. Sonia Vallet
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
OA Univ.-Prof. Mag. DDr. Klaus Podar
Head of
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
